Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient

T cell–mediated rejection that appears and persists late after transplantation is often associated with development of de novo donor-specific antibodies. Treatment of this condition often presents a conundrum because of the uncertainty regarding the trade-off between immunosuppression-related toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Klintmalm, Göran B., Trotter, James F., Demetris, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Liver Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236599/
https://www.ncbi.nlm.nih.gov/pubmed/35774420
http://dx.doi.org/10.1097/TXD.0000000000001076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236599/
https://www.ncbi.nlm.nih.gov/pubmed/35774420
http://dx.doi.org/10.1097/TXD.0000000000001076

Ejemplares similares